1183 Objectives: Bone metastases of prostate cancer are often associated with a poor
clinical outcome. Therefore, the concise characterisation of bone involvement is clinically …

Prostate-specific membrane antigen (PSMA) PET/CT has a high diagnostic accuracy for
lesion detection in metastatic prostate cancer, including bone metastases. Novel therapeutic …

Prostate specific membrane antigen (PSMA) PET/CT has become a standard diagnostic
procedure for whole body prostate cancer staging. The application of texture analysis to PET …

563 Objectives PET with 68Ga-labelled PSMA inhibitors is an emerging imaging technique
increasingly used for PC workup. On the other hand, bone scintigraphy (BS) with 99mTc …

PET combined with CT and prostate-specific membrane antigen (PSMA) ligands has gained
significant interest for staging prostate cancer (PC). In this study, we propose 2 multimodal …

Purpose 68 Gallium-labeled prostate-specific membrane antigen-11 (PSMA) PET/CT is the
new reference to identify relapse during biochemical recurrence of prostate cancer (PCa) …

Purpose Uncertain focal bone uptake (UBU) with intensive radiopharmaceutical avidity are
frequently observed in patients undergoing [18F] PSMA-1007 PET/CT for the detection of …

Purpose The aim of our study was to compare the diagnostic performance of 68 Ga-PSMA
PET and 99m Tc bone scintigraphy (BS) for the detection of bone metastases in prostate …

Simple Summary Treating patients for metastatic prostate cancer based on the information of
PSMA-PET bears the risk to “under-or overtreat” patients, given that many lesions seen only …

Purpose The aims of this retrospective analysis were to compare 68 Ga-PSMA PET findings
and low-dose CT findings (120 kV, 30 mA), and to obtain semiquantitative and quantitative …